The U.S. Food and Drug Administration's final approval of Alembic Pharmaceuticals' abbreviated new drug application for Fingolimod capsules — therapeutically equivalent to Novartis's Gilenya — is expected to trigger immediate market entry discussions as the company moves to commercialise the product in the United States, industry analysts said Tuesday.

Fingolimod, an oral sphingosine-1-phosphate receptor modulator, is one of the most prescribed disease-modifying therapies for relapsing-remitting multiple sclerosis. Gilenya generated hundreds of millions of dollars annually at peak sales before earlier generic entrants began eroding Novartis's share. Alembic's approval adds a further competitor to that generic field, putting additional downward pressure on pricing that could benefit the roughly 400,000 Americans living with MS who rely on the drug.

Alembic Pharmaceuticals, headquartered in Vadodara, India, has steadily built its U.S. generics portfolio through a pipeline of complex oral solid dosage forms. The company's regulatory affairs team confirmed the approval meets all FDA bioequivalence and labelling standards, clearing the path for distribution agreements with major U.S. wholesalers including McKesson, AmerisourceBergen, and Cardinal Health.

The timing is notable given broader momentum in generic drug access in the United States. The recent Cost Plus Drug pricing model adopted by BMS and Pfizer for Eliquis has intensified scrutiny of brand-name pricing, and patient advocacy groups for neurological conditions have pointed to Fingolimod as a drug where generic competition remains insufficiently robust to drive prices down to widely affordable levels.

Analysts at IQVIA estimate the U.S. Fingolimod generic market could approach $180 million annually across all approved manufacturers. Alembic shares rose modestly on Indian exchanges following the approval news, with investors anticipating launch preparations in the coming weeks. The company has not confirmed a specific commercial launch date but is expected to address timelines during its quarterly earnings call scheduled for late April.